Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 from Investment in Questcor Pharmaceuticals, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before The November 26, 2012 Lead Plaintiff Dead

STEVENSON, Md., Oct. 1, 2012 (GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of the common stock of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company") (Nasdaq:QCOR) during the period between April 26, 2011 and September 21, 2012, inclusive (the "Class Period").

If you have suffered a net loss for all transactions in Questcor Pharmaceuticals, Inc. common stock during the Class Period, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than November 26, 2012 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the Company's failure to disclose during the Class Period that the Company lacked clinical evidence to support the use of Acthar for indications other than infantile spasms and that the Company had engaged in questionable tactics to promote the sale and use of Acthar in the treatment of MS and nephrotic syndrome. After, on September 19, 2012, a Citron Research reported that Aetna, Inc., in a clinical policy bulletin, indicated that studies suggested that Acthar was only medically necessary for one of 19 indications for which the FDA had approved the drug, the value of Questcor shares declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

CONTACT: Charles J. Piven Brower Piven, A Professional Corporation Stevenson, Maryland 410/415-6616 hoffman@browerpiven.comSource: Brower Piven, A Professional Corporation